Tapentadol extended release in the management of peripheral diabetic neuropathic pain

被引:30
|
作者
Vadivelu, Nalini [1 ]
Kai, Alice [2 ]
Maslin, Benjamin [1 ]
Kodumudi, Gopal [3 ]
Legler, Aron [1 ]
Berger, Jack M. [4 ]
机构
[1] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA
[2] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
[3] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA
[4] Univ So Calif, Keck Sch Med, Dept Anesthesiol, Los Angeles, CA 90033 USA
关键词
chronic pain; neuropathic pain; pharmacology; analgesia; pain management; OPIOID RECEPTOR AGONIST; LOW-BACK-PAIN; OXYCODONE CONTROLLED-RELEASE; RANDOMIZED CONTROLLED-TRIAL; INDUCED BOWEL DYSFUNCTION; DOUBLE-BLIND; PROLONGED-RELEASE; CHRONIC OSTEOARTHRITIS; PHARMACOLOGICAL MANAGEMENT; MORPHINE ANALGESIA;
D O I
10.2147/TCRM.S32193
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Tapentadol, a mu-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.
引用
收藏
页码:95 / 105
页数:11
相关论文
共 50 条
  • [41] Management of diabetic neuropathic pain: lessons from a specialist neuropathic pain clinic
    Vas, P. R. J.
    Manu, C.
    Bates, M.
    Mahdi-Rogers, M.
    Edmonds, M. E.
    DIABETIC MEDICINE, 2016, 33 : 162 - 162
  • [42] Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
    Papanas, Nikolaos
    Ziegler, Dan
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (04) : 393 - 407
  • [43] Duloxetine effective in the treatment of diabetic peripheral neuropathic pain
    Quilici, S.
    Chancellor, J.
    Loethgren, M.
    SA PHARMACEUTICAL JOURNAL, 2009, 76 (06) : 48 - 48
  • [44] Safety profile of treatment in diabetic peripheral neuropathic pain
    Robinson-Papp, Jessica
    Simpson, David M.
    PAIN MEDICINE, 2007, 8 : S43 - S49
  • [45] Diabetic Peripheral Neuropathic Pain: Is Gabapentin Effective? REPLY
    Lindsay, Tammy J.
    Rodgers, Blake C.
    Savath, Vincent
    Hettinger, Kevin
    Herndon, Chris M.
    AMERICAN FAMILY PHYSICIAN, 2011, 84 (05) : 482 - 482
  • [46] Quality of life in veterans with diabetic peripheral neuropathic pain
    Masheb, R.
    LaChappelle, K.
    Heapy, A.
    Higgins, D.
    Czlapinski, R.
    Kulas, J.
    Kerns, R.
    JOURNAL OF PAIN, 2014, 15 (04): : S17 - S17
  • [47] Managing diabetic peripheral neuropathic pain in primary care
    Kuritzky, Louis
    JOURNAL OF FAMILY PRACTICE, 2010, 59 (05): : S15 - S22
  • [48] Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain
    Coluzzi, Flaminia
    Ruggeri, Matteo
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (06) : 1139 - 1151
  • [49] Epidemiology, pathogenesis and treatment of diabetic peripheral neuropathic pain
    Tesfaye, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 322 - 322
  • [50] Dose Conversion Between Tapentadol Immediate and Extended Release for Low Back Pain
    Etropolski, Mila S.
    Okamoto, Akiko
    Shapiro, Douglas Y.
    Rauschkolb, Christine
    PAIN PHYSICIAN, 2010, 13 (01) : 61 - 70